Pharma: Page 10
-
Daniel Tadevosyan via Getty Images
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi.
By BioPharma Dive staff • Dec. 13, 2024 -
Stock via Getty Images
With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.
By Jonathan Gardner • Updated Dec. 11, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Daniel Tadevosyan via Getty Images
BenevolentAI restructures; Lilly preps $15B buyback program
The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.
By BioPharma Dive staff • Updated Dec. 17, 2024 -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical ServicesClinical services organizations are critical to the future of pharma in the APAC market
As APAC contract manufacturing grows, pharma companies turn to outsourcing for cost-effective solutions.
Dec. 9, 2024 -
kirisa99/istockphoto.com
Sponsored by EvaluateWhat’s behind pharma’s growth boost?
Pharma is forecast for a 7.7% growth rate to 2030. What’s driving it? (hint: it’s not just obesity).
Dec. 9, 2024 -
Scott Olson via Getty Images
Lilly adds to obesity drug production push with $3B investment
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.
By Jonathan Gardner • Dec. 6, 2024 -
Daniel Tadevosyan via Getty Images
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.
By BioPharma Dive staff • Dec. 6, 2024 -
Daniel Tadevosyan via Getty Images
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
By BioPharma Dive staff • Dec. 4, 2024 -
Scott Olson via Getty Images
Obesity drugsLilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
By Jonathan Gardner • Updated Dec. 4, 2024 -
Daniel Tadevosyan via Getty Images
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a key PDUFA date and Fate Therapeutics swapped CEOs.
By BioPharma Dive staff • Dec. 2, 2024 -
Daniel Tadevosyan via Getty Images
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
By BioPharma Dive staff • Nov. 27, 2024 -
hapabapa via Getty Images
Obesity drugsAmgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
By Jonathan Gardner • Nov. 26, 2024 -
Roche’s TIGIT-targeting drug for cancer fails its biggest test
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in a closely followed Phase 3 study called SKYSCRAPER-01.
By Ned Pagliarulo • Nov. 26, 2024 -
Marko Georgiev / Stringer via Getty Images
New data could help Merck expand use of cardiovascular drug
Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent expirations this decade.
By Jonathan Gardner • Nov. 25, 2024 -
Daniel Tadevosyan via Getty Images
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.
By BioPharma Dive staff • Nov. 22, 2024 -
Jacob Bell/BioPharma Dive
Amgen picks prolific biotech founder Chang as new top scientist
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.
By Kristin Jensen • Nov. 21, 2024 -
George Clerk via Getty Images
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
By Kristin Jensen • Nov. 20, 2024 -
Courtesy of Merck & Co.
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.
By Jonathan Gardner • Nov. 19, 2024 -
Daniel Tadevosyan via Getty Images
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.
By BioPharma Dive staff • Nov. 19, 2024 -
Mario Tama via Getty Images
J&J pill clears skin in two late-stage psoriasis studies
The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down the inflammation involved in psoriasis and other immune diseases.
By Ned Pagliarulo • Nov. 19, 2024 -
Daniel Tadevosyan via Getty Images
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.
By BioPharma Dive staff • Nov. 15, 2024 -
Marko Georgiev / Stringer via Getty Images
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial.
By Ben Fidler • Nov. 14, 2024 -
Daniel Tadevosyan via Getty Images
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.
By BioPharma Dive staff • Nov. 13, 2024 -
Mario Tama via Getty Images
J&J sues US government for halting 340B rebate plan
The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.
By Rebecca Pifer • Nov. 13, 2024 -
SciePro via Getty Images
AstraZeneca, Daiichi revise approval plans for Enhertu successor
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and instead are aiming for a narrower approval.
By Ben Fidler • Nov. 12, 2024
Previous
